EcoDrugPlus

Phosphoinositide-3-Kinase, Regulatory Subunit 2 (Beta)

Ensembl ID : ENSACIG00000020433
Gene Symbol: PIK3R2
1 Cross references
190 Possible Orthologues:

Phospholipase A2 Group X

Ensembl ID : ENSACIG00000005376
Gene Symbol: PLA2G10
1 Cross references
233 Possible Orthologues:

Phospholipase A2, Group Vii (Platelet-Activating Factor Acetylhydrolase, Plasma)

Ensembl ID : ENSACIG00000012654
Gene Symbol: PLA2G7
1 Cross references
206 Possible Orthologues:

Phosphoribosylglycinamide Formyltransferase

Ensembl ID : ENSACIG00000017036
Gene Symbol: GART
1 Cross references
214 Possible Orthologues:

Plasminogen Activator, Tissue Type

Ensembl ID : ENSACIG00000018518
Gene Symbol: PLAT
1 Cross references
207 Possible Orthologues:

Platelet Activating Factor Receptor

Ensembl ID : ENSACIG00000014145
Gene Symbol: PTAFR
1 Cross references
223 Possible Orthologues:

Platelet Activating Factor Receptor

Ensembl ID : ENSACIG00000017080
Gene Symbol: PTAFR
1 Cross references
223 Possible Orthologues:

Platelet-Derived Growth Factor Receptor, Beta Polypeptide

Ensembl ID : ENSACIG00000016124
Gene Symbol: PDGFRB
1 Cross references
199 Possible Orthologues:

Polo Like Kinase 1

Ensembl ID : ENSACIG00000023696
Gene Symbol: PLK1
2 Cross references
187 Possible Orthologues:

Poly (Adp-Ribose) Polymerase 2

Ensembl ID : ENSACIG00000012715
Gene Symbol: PARP2
1 Cross references
186 Possible Orthologues:

Poly (Adp-Ribose) Polymerase Family, Member 3

Ensembl ID : ENSACIG00000020765
Gene Symbol: PARP3
1 Cross references
199 Possible Orthologues:

Porcupine O-Acyltransferase

Ensembl ID : ENSACIG00000010418
Gene Symbol: PORCN
1 Cross references
195 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).